Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies [0.03%]
双特异性抗CD3×抗CD155抗体介导T细胞免疫治疗人类血液系统恶性肿瘤
Li Ma,Juan Ma,Xin Sun et al.
Li Ma et al.
T cells are important components in the cell-mediated antitumour response. In recent years, bispecific antibodies (Bi-Abs) have become promising treatments because of their ability to recruit T cells that kill tumours. Here, we demonstrate ...
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors [0.03%]
一项Ⅰb期研究：评估选择性Wee1抑制剂艾達沃西替尼（adavosertib）用于局部晚期或转移性实体瘤患者的疗效和安全性
Gerald S Falchook,Jasgit Sachdev,Esteban Rodrigo Imedio et al.
Gerald S Falchook et al.
Adavosertib selectively inhibits Wee1, which regulates intra-S and G2/M cell-cycle checkpoints. This study investigated dosing schedules for adavosertib monotherapy, determining the maximum tolerated dose (MTD) and recommended Phase II dose...
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors [0.03%]
新型DNA修复抑制剂talazoparib治疗晚期实体瘤的药代动力学、安全性和抗肿瘤活性：中国患者的临床I期试验结果
Yang Luo,Ying Cheng,Chunjiao Wu et al.
Yang Luo et al.
Talazoparib, a poly(ADP-ribose) polymerase inhibitor, has demonstrated efficacy in the treatment of advanced breast and prostate cancers in Western populations. This open-label, phase 1 study investigated the pharmacokinetics, safety, and a...
Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis [0.03%]
伴有腹部疼痛、血清炎症标志物和胆管酶升高的免疫检查点抑制剂诱导的硬化性胆管炎的诊断
Takafumi Yamamoto,Kazuyuki Mizuno,Takanori Ito et al.
Takafumi Yamamoto et al.
Immune-related sclerosing cholangitis (irSC) is relatively rare and its clinical characteristics are not well known. In this study, we aimed to summarize the clinical features of irSC. Clinical data were collected retrospectively from 1,393...
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies [0.03%]
题为“一项肿瘤选择性腺病毒载体平台在I期临床研究中诱导暂时抗磷脂抗体的更正：无增加血栓风险” 的更正发表通知
Danny N Khalil,Isabel Prieto González-Albo,Lee Rosen et al.
Danny N Khalil et al.
Published Erratum
Investigational new drugs. 2023 Jun;41(3):539. DOI:10.1007/s10637-023-01369-0 2023
Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles [0.03%]
日本患者和非日本患者抗肿瘤药物安全结果的多区域临床试验对比：安全特征的Meta分析
Toshiyuki Tamai,Mamoru Narukawa
Toshiyuki Tamai
No report has assessed the differences in adverse event (AE) profiles of anticancer drugs for all types of cancers in clinical trials involving Japanese patients. This study aimed to compare the safety outcomes of anticancer drugs in Japane...
Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth [0.03%]
表观遗传调控因子单独或以特定组合抑制胶质母细胞瘤干细胞系的增殖，但对正常神经干/祖细胞影响较小
Arshak R Alexanian,Heidi Marie Stoellinger,Virginea de Araujo Farias et al.
Arshak R Alexanian et al.
Glioblastomas (GBM), also known as glioblastoma multiforme, are the most aggressive type of brain cancer. Currently, there is no effective treatment for GBM, highlighting the pressing need for new therapeutic strategies. In a recent study, ...
HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial [0.03%]
抗HER-2单克隆抗体 HLX22 治疗 HER2 高表达的晚期实体瘤患者的一项 I 期开放标记剂量递增试验
Xiaoxue Zhu,Yanhua Ding,Qian Wang et al.
Xiaoxue Zhu et al.
HLX22 is a novel monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). This first-in-human, phase 1 dose-escalation study aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of...
Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients [0.03%]
艾维替尼治疗EGFR阳性晚期非小细胞肺癌患者预后预测模型的建立及影响预后的因素分析
Xueyun Tan,Sufei Wang,Hui Xia et al.
Xueyun Tan et al.
Clinical trials on icotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), have shown promising results as targeted therapy for non-small cell lung cancer (NSCLC). This study aimed to establish an...
Xiao-Yang Gong,Hai-Bing Chen,Zhao-Yi Lu et al.
Xiao-Yang Gong et al.